Researchers at Children’s Hospital of Philadelphia and
the School of Engineering and Applied Science at the University of
Pennsylvania have identified ionizable lipid nanoparticles that
could be used to deliver mRNA as part of fetal therapy. The
proof-of-concept study, published today in Science Advances,
engineered and screened a number of lipid nanoparticle formulations
for targeting mouse fetal organs and has laid the groundwork for
testing potential therapies to treat genetic diseases before
birth.
Researchers identify nanoparticles that could deliver
therapeutic mRNA before birth
